Speaker
Tracey Mullen, VP/GM
Mice are one of the most common repertoire sources for in vivo antibody discovery. The choice of mouse model, immunization method, and/or screening strategy can significantly impact the drug discovery and development timeline. In this webinar, the scientific leadership of Abveris will discuss the following topics:
1. Challenges in the discovery of therapeutic antibodies against cell surface receptors and transmembrane proteins such as GPCR and ion channels
2. Overview of key selected technologies to access development-ready therapeutic leads, including the use of humanized mice and humanization of murine antibodies
3. A case study of an antibody discovery campaign against a cell surface receptor target using both humanized mice and proprietary hyperimmune (DiversimAb) mice for a risk-mitigated workflow under a rapid timeline
Overview of screening technologies for anti-Id antibodies discovery.
Dos and don'ts when planning and designing anti-Id discovery campaigns
Case studies of hybridoma-based and Beacon-based anti-Id campaigns targeting therapeutic biologics
Click the link below to schedule a meeting with one of our scientists!
